Boston Scientific Corporation (NYSE:BSX) Given Consensus Recommendation of "Buy" by Analysts

Key Points

• Boston Scientific Corporation has received a consensus rating of "Buy" from 27 analysts, with an average 12-month target price of $120.71.
• In recent research reports, various firms have updated their price targets for the company, with Barclays raising its target to $136.00 and Raymond James to $124.00, both maintaining positive ratings.
• Insider trading activity showed significant stock sales, including a 21.90% decrease in ownership by EVP Joseph Michael Fitzgerald after selling 50,000 shares for approximately $4.92 million.

Shares of Boston Scientific Corporation (NYSE:BSX - Get Free Report) have been assigned a consensus rating of "Buy" from the twenty-seven analysts that are presently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation, twenty-three have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month target price among brokers that have covered the stock in the last year is $120.7083.

BSX has been the subject of a number of recent research reports. Barclays raised their price objective on shares of Boston Scientific from $133.00 to $136.00 and gave the stock an "overweight" rating in a research note on Thursday, October 2nd. Raymond James Financial raised their price target on Boston Scientific from $121.00 to $124.00 and gave the stock a "strong-buy" rating in a research report on Thursday, July 24th. UBS Group raised their price target on Boston Scientific from $130.00 to $135.00 and gave the stock a "buy" rating in a research report on Thursday, July 24th. Robert W. Baird raised their price target on Boston Scientific from $123.00 to $128.00 and gave the stock an "outperform" rating in a research report on Wednesday, October 1st. Finally, Needham & Company LLC reiterated a "buy" rating and set a $121.00 price objective on shares of Boston Scientific in a research report on Wednesday, October 1st.

Insider Activity

In other Boston Scientific news, Director Edward J. Ludwig sold 4,000 shares of Boston Scientific stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $106.03, for a total value of $424,120.00. Following the completion of the sale, the director directly owned 18,479 shares of the company's stock, valued at approximately $1,959,328.37. The trade was a 17.79% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $98.47, for a total transaction of $4,923,500.00. Following the completion of the sale, the executive vice president directly owned 178,342 shares of the company's stock, valued at $17,561,336.74. The trade was a 21.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 174,214 shares of company stock valued at $17,972,457. 0.50% of the stock is owned by corporate insiders.

Institutional Trading of Boston Scientific

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Great Waters Wealth Management grew its holdings in Boston Scientific by 64.0% in the 3rd quarter. Great Waters Wealth Management now owns 5,769 shares of the medical equipment provider's stock valued at $563,000 after buying an additional 2,251 shares during the period. Westwind Capital purchased a new stake in Boston Scientific in the third quarter valued at approximately $13,799,000. Farther Finance Advisors LLC grew its holdings in Boston Scientific by 37.5% in the third quarter. Farther Finance Advisors LLC now owns 17,982 shares of the medical equipment provider's stock valued at $1,756,000 after purchasing an additional 4,903 shares during the period. Security Financial Services INC. purchased a new stake in Boston Scientific in the third quarter valued at approximately $384,000. Finally, HBK Sorce Advisory LLC grew its stake in shares of Boston Scientific by 13.0% during the 3rd quarter. HBK Sorce Advisory LLC now owns 9,617 shares of the medical equipment provider's stock valued at $931,000 after buying an additional 1,110 shares during the period. Hedge funds and other institutional investors own 89.07% of the company's stock.

Boston Scientific Trading Up 1.4%

Shares of BSX stock opened at $96.26 on Wednesday. Boston Scientific has a fifty-two week low of $80.64 and a fifty-two week high of $109.50. The stock has a market cap of $142.63 billion, a P/E ratio of 57.30, a P/E/G ratio of 2.29 and a beta of 0.61. The business has a fifty day simple moving average of $101.58 and a 200-day simple moving average of $101.80. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts' consensus estimates of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business had revenue of $5.06 billion during the quarter, compared to analysts' expectations of $4.89 billion. During the same quarter last year, the business posted $0.62 earnings per share. The business's revenue for the quarter was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, analysts forecast that Boston Scientific will post 2.85 earnings per share for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.